Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson’s disease through AKT/mTOR pathway

• DOI: 10.18632/aging.103225
• Publication Date: 2020-05-18T22:04:40Z
• Authors: Liangqin Shi; Chao Huang; Qihui Luo; Yu Xia; Wentao Liu; Wen Zeng; Anchun Cheng; Riyi Shi; Chen Zhengli
• Keywords: MPTP; Clioquinol; Pathogenesis

Despite decades of research into the pathology mechanisms Parkinson's disease (PD), disease-modifying therapy PD is scarce.Thus, searching for new drugs or more effective neurosurgical treatments has elicited much interest.Clioquinol (CQ) been shown to have therapeutic benefits in rodent models neurodegenerative disorders.However, it's neuroprotective role and primate patients, especially advanced stages, are not fully understood.Furthermore, issues such as spontaneous recovery motor function high symptom variability different monkeys after same toxic protocol, resolved before present study.In this study, we designed a chronic long-term progressive protocol generate stabilized monkey model showed with classic non-motor deficits, followed by treatment analysis CQ.We found that CQ could remarkably improve which were based on reduction iron content ROS level SN further improvement pathology.Meanwhile, also ferroptosis was probably involved pathogenesis PD.In addition, study shows positive effect AKT/mTOR survival pathway blocking p53 medicated cell death vivo vitro.